Philippines Liver Diseases Therapeutics Market Report 2022 to 2030

Philippines Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Philippines Liver Disease Therapeutics market will reach a value of $82 Mn from $51 Mn in 2022, growing at a CAGR of 6.2% during 2022-2030. Liver Disease Therapeutics in the Philippines is dominated by a few domestic pharmaceutical companies such as Pascual Laboratories, United Laboratories, and Natrapharm. The Liver Disease Therapeutics market in the Philippines is segmented into different types of disease and different therapy types. Some of the major factors affecting the Philippine's Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10PHPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Phillipines AUTHOR: Dr. Vishwa Modhia

Buy Now

Philippines Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Philippines Liver Disease Therapeutics market will reach a value of $82 Mn from $51 Mn in 2022, growing at a CAGR of 6.2% during 2022-2030.

The Philippines is a low-middle-income developing country in Southeast Asia in the western Pacific Ocean. At least 18 Mn Filipinos are either suffering from or are in danger of developing fatty liver disease, which is referred to as a "silent epidemic." This is one of the disturbing facts highlighted during the Hepatology Society of the Philippines' recent online press conference titled "Fatty Liver Facts: What You Need to Know About This Silent Epidemic" (HSP). Alternative therapies, such as traditional Chinese medicine and acupuncture, are utilised to treat liver illness in the Philippines in addition to established medical treatments.

According to the latest WHO data published in 2020 Liver Disease Deaths in the Philippines reached 7,076 or 1.05% of total deaths. The age-adjusted Death Rate is 8.65 per 100,000 population ranks the Philippines 135^th in the world. The Philippines' government spent 5.1% of its GDP on healthcare in 2020.

Philippines Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

The government has launched a national hepatitis B vaccination programme, and antiviral medicines are available to treat chronic hepatitis B and C. The Philippines has multiple liver transplant hospitals in Manila, where patients with end-stage liver disease can receive liver transplantation. The Philippines' Business Process Outsourcing (BPO) industry is thriving. These aspects could boost Philippines Liver Disease Therapeutics market.

Market Restraints

The healthcare system in the Philippines is decentralised, with both government-run and private establishments providing healthcare services. This can lead to discrepancies in access and quality of care, especially in rural areas. The expense of liver disease therapy in the Philippines can be prohibitive for certain patients. Individuals who require medical care but cannot afford it are eligible for government subsidies and financial assistance. The Philippines suffers from severe income inequality and underemployment, which encourages expatriation. These factors may deter new entrants into the Philippines Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Pascual Laboratories: Pascual Laboratories is a Philippine pharmaceutical company that produces a range of therapeutic products, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silymarin
Natrapharm: Natrapharm is a Philippine pharmaceutical company that produces a variety of therapeutics, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silymarin
United Laboratories: United Laboratories is a Philippine pharmaceutical company that produces a range of therapeutics, including those for liver disease
Ethical Pharma: Ethical Pharma is a Philippine pharmaceutical company that produces a range of therapeutic products, including those for liver disease

Recent Notable Updates

February 2023: Tanco-led Maestro Holdings and Reliance United, a subsidiary of United Laboratories (Unilab), the leading pharmaceutical company in the Philippines and Southeast Asia, have formed a partnership that will provide access to Reliance United’s full-service Healthfirst Clinic to members of the pioneering health maintenance organisation PhilCare. The collaboration validates the two companies' dedication to providing the greatest healthcare services to their clients and solidifies their position as two of the most active institutions in the country's healthcare market.

Healthcare Policies and Reimbursement Scenarios

The Food and Drug Administration (FDA) and the Philippine Health Insurance Corporation (PhilHealth) are in charge of the regulation and payment of liver treatments in the Philippines, respectively. Chronic liver disease patients may also be eligible for specialised care through the Department of Health's Liver Transplant Program, which offers diagnostic tests, specialist consultations, and liver transplant services. In terms of reimbursement, PhilHealth, the government-funded healthcare system, pays the cost of liver treatments for qualifying patients.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.